Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Whitehawk Therapeutics (WHWK) EBITDA Margin: 2018-2025

Historic EBITDA Margin for Whitehawk Therapeutics (WHWK) over the last 4 years, with Mar 2025 value amounting to 1,021.71%.

  • Whitehawk Therapeutics' EBITDA Margin rose 136402.00% to 1,021.71% in Q1 2025 from the same period last year, while for Mar 2025 it was 99.45%, marking a year-over-year increase of 38807.00%. This contributed to the annual value of -245.17% for FY2024, which is 2429.00% up from last year.
  • According to the latest figures from Q1 2025, Whitehawk Therapeutics' EBITDA Margin is 1,021.71%, which was up 504.25% from -252.74% recorded in Q4 2024.
  • Whitehawk Therapeutics' EBITDA Margin's 5-year high stood at 55,470.06% during Q3 2021, with a 5-year trough of -3,405.83% in Q1 2021.
  • Moreover, its 3-year median value for EBITDA Margin was -256.50% (2023), whereas its average is -117.81%.
  • In the last 5 years, Whitehawk Therapeutics' EBITDA Margin soared by 5,682,894bps in 2021 and then tumbled by 5,581,336bps in 2022.
  • Quarterly analysis of 5 years shows Whitehawk Therapeutics' EBITDA Margin stood at -118.84% in 2021, then slumped by 14,765bps to -266.48% in 2022, then spiked by 998bps to -256.50% in 2023, then skyrocketed by 375bps to -252.74% in 2024, then soared by 136,402bps to 1,021.71% in 2025.
  • Its EBITDA Margin was 1,021.71% in Q1 2025, compared to -252.74% in Q4 2024 and -173.04% in Q3 2024.